Epiproteomics of Sezary Syndrome

塞扎里综合征的表观蛋白质组学

基本信息

批准号：
10632068
负责人：
KOJO S. J. ELENITOBA-JOHNSON
金额：
$ 56.66万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10632068
关键词：
Address Aggressive Clinical Course Antineoplastic Agents Behavior Biological Assay Biological Markers Biological Process Blood CD4 Positive T Lymphocytes CLIA certified Chemicals Clinical Credentialing Cutaneous T-cell lymphoma Data Detection Development Diagnosis Diagnostic Disease Early Diagnosis Exhibits Flow Cytometry Gene Expression Goals Histone Code Histone Deacetylase Inhibitor Histone Deacetylation Histones Individual Indolent Infiltration Laboratories Learning Life Expectancy Lymphoid Malignant Neoplasms Mass Spectrum Analysis Measurement Measures Modeling Modification Mycosis Fungoides Nature Neoplasm Circulating Cells Outcome Pathogenesis Patients Peripheral Pharmaceutical Preparations Prediction of Response to Therapy Prospective cohort Resources Retrospective cohort Sampling Sezary Syndrome Skin Skin Cancer Staging Subcategory T-Cell Lymphoma Testing Therapeutic Effect Time Tumor Burden Validation Variant accurate diagnosis cohort diagnostic accuracy diagnostic biomarker diagnostic criteria diagnostic tool improved improved outcome indexing innovation mortality neoplastic cell novel patient response predict responsiveness predicting response predictive marker response skin lesion targeted treatment treatment response

Address Aggressive Clinical Course Antineoplastic Agents Behavior Biological Assay Biological Markers Biological Process Blood CD4 Positive T Lymphocytes CLIA certified Chemicals Clinical Credentialing Cutaneous T-cell lymphoma Data Detection Development Diagnosis Diagnostic Disease Early Diagnosis Exhibits Flow Cytometry Gene Expression Goals Histone Code Histone Deacetylase Inhibitor Histone Deacetylation Histones Individual Indolent Infiltration Laboratories Learning Life Expectancy Lymphoid Malignant Neoplasms Mass Spectrum Analysis Measurement Measures Modeling Modification Mycosis Fungoides Nature Neoplasm Circulating Cells Outcome Pathogenesis Patients Peripheral Pharmaceutical Preparations Prediction of Response to Therapy Prospective cohort Resources Retrospective cohort Sampling Sezary Syndrome Skin Skin Cancer Staging Subcategory T-Cell Lymphoma Testing Therapeutic Effect Time Tumor Burden Validation Variant accurate diagnosis cohort diagnostic accuracy diagnostic biomarker diagnostic criteria diagnostic tool improved improved outcome indexing innovation mortality neoplastic cell novel patient response predict responsiveness predicting response predictive marker response skin lesion targeted treatment treatment response

展开

项目摘要

PROJECT SUMMARY EPIPROTEOME OF SEZARY SYNDROME Peripheral T-cell lymphomas including cutaneous T-cell lymphomas (CTCL) are poorly understood and many subtypes exhibit aggressive clinical course and high mortality with short (2-year) life expectancy after diagnosis. Poor understanding of mechanisms underlying the pathogenesis of CTCLs contributes to suboptimal diagnostic subcategorization and lack of targeted therapies. Mycosis fungoides (MF) and Sézary syndrome (SS) are two major forms of CTCL. Clinical staging and outcome of MF and SS is dependent on the quantity of neoplastic cells in the blood. While SS is an aggressive disease with poor overall survival (42.3% at 5 years and is by definition diagnosed at late stage disease, there are many patients with low tumor burden (Early-stage CTCL) who suffer from delay in diagnosis due to the subjective nature of the diagnostic criteria. The mean diagnostic delay (measured as the time from emergence of skin lesions to the diagnosis of SS) is long (4.2 year; median 2.8 years) with a significant variation (1 month to 32 years). The suboptimal diagnostic accuracy and imprecision of disease detection necessitates the development of qualitative and objective biomarkers of SS. Histone deacetylase inhibitors (HDACi) have been introduced as anti- cancer agents which achieve their therapeutic effect in part by inhibiting deacetylation of histones. However, despite the fact that CTCLs including SS were the first diseases which received FDA approval for treatment with HDACi, responses to the drugs in each patient are markedly variable. An unmet clinical need is the absence of reliable biomarkers directly interrogating the histone PTMs that can predict response to the drugs. We recently developed a novel mass spectrometry (MS)-based strategy for unbiased identification of histone PTMs and demonstrated its applicability for the analysis of primary samples of SS. Importantly, these epiproteomic profiling studies reveal distinctive histone PTM marks that distinguish SS from CD4+ T-cells from healthy individuals. It is our central hypothesis that epiproteomic modifications (the histone code) of SS can be utilized for the early diagnosis and as predictors of response to HDACi. Accordingly, we propose to investigate the utility of MS-based epiproteomic profiling for the early diagnosis of SS and for the prediction of response to HDACi. The overall impact of this proposal is the establishment of novel epiproteomic biomarkers that will improve outcomes particularly in aggressive CTCLs.

项目摘要发作综合征的附生组包括皮肤T细胞淋巴瘤（CTCL）的外周T细胞淋巴瘤知之甚少，并且许多亚型暴露了积极进取的临床课程和高死亡率，较短（2年）的预期寿命诊断。对CTCL发病机理的基础机制的不良理解有助于次级诊断亚分类和缺乏靶向疗法。真菌病真菌（MF）和Sézary 综合征（SS）是CTCL的两种主要形式。 MF和SS的临床分期和结果取决于血液中肿瘤细胞的数量。虽然SS是一种侵略性疾病，总生存率较差（在5年时为42.3％，根据定义在晚期疾病处被诊断出，许多患者有很多肿瘤负担（早期CTCL）因主题性质而受到诊断延迟诊断标准。平均诊断延迟（以皮肤病变的出现到 SS的诊断为长（4。2年；中位2。8年），其差异很大（1个月至32年）。这必要 SS的定性和客观生物标志物。组蛋白脱乙酰基酶抑制剂（HDACI）已经作为抗癌剂引入，通过抑制脱乙酰化的部分来达到其治疗作用希腊。但是，尽管包括包括SS在内的CTCL是接受FDA的第一批疾病用HDACI治疗的批准，每位患者中对药物的反应是明显变化的。一个未满足的临床需求是没有可靠的生物标志物直接询问可以预测的组蛋白PTM 对药物的反应。我们最近开发了一种新型的质谱法（MS）的公正策略鉴定组蛋白PTM，并证明了其适用于分析SS的主要样品的适用性。重要的是，这些附生蛋白质组织研究揭示了区分SS的独特组蛋白PTM标记来自健康个体的CD4+ T细胞。我们的核心假设是增生蛋白质组学修饰（组蛋白代码）SS可以用于早期诊断，并作为对 hdaci。根据，我们建议研究早期基于MS基于MS的表现型分析的实用性 SS的诊断和预测对HDACI的反应。该提议的总体影响是建立新型的表现蛋白质组学生物标志物，这些标志物将改善结果，特别是在侵略性方面 CTCL。